20/20 Onsite

Home
United States
Boston, MA
20/20 Onsite

20/20 Onsite delivers comprehensive eye exams to businesses via a state-of-art mobile vision center.

20/20 Onsite (also known as 2020 Onsite) is the only provider solely dedicated to point-of-need eye assessments for clinical trials, proven to meet screening timelines, improve retention rates, and fast-track trials. This is a great way for companies to offer a unique, low-cost benefit to employees.

06/22/2026

Meet Dr. Shelby Brogdon, OD, dry eye clinic owner, practice builder, and the OD who showed up for her patient through a snowstorm because that's just what the work requires.

Her journey with 20/20 Onsite started at a crossroads:
"I got involved with 20/20 Onsite about a year ago during a time when I was feeling pretty burnt out in my previous role and was looking for ways to create more flexibility in my schedule."

What changed everything?
"Working with 20/20 Onsite fits seamlessly into that shift. It gave me the opportunity to stay clinically engaged while building a schedule that was more sustainable and aligned with my long-term goals.”

What keeps her committed to the work:
"It allows me to serve patients in my own community who may not otherwise have access to clinical research opportunities. Being able to bring that level of care closer to home is incredibly meaningful."

Her most memorable moment says everything about the culture:
"One of the most memorable experiences was coordinating care for a patient during a stretch of snowy weather. We had deadlines to meet, and despite the conditions, the team worked together to make sure we could still reach the patient and provide the care they needed.”

When asked what it takes to thrive in this role, she's clear:
"Flexibility and adaptability are key. Most importantly, though, you have to genuinely care about providing high-quality patient care. When you combine that mindset with flexibility, it creates a really rewarding experience.”

Dr. Brogdon's story is for every OD who has felt the weight of routine and wondered if there was a way to practice differently without starting over.

Are you an OD looking for:
- Flexibility that fits around a practice you've already built
- The chance to bring clinical research to patients in your own community
- A team that's prepared and ready when you walk through the door
- Work that balances sustainability with meaningful patient care
- A role that complements ownership without competing with it

Join our OD Network. 📩 Interested in learning more? Set up a quick chat with Dr. Katherine Harkins, Director of Optometry, at [email protected]

06/16/2026

Efficiency gets the work done. Flexibility keeps the work moving when things go sideways.

Our CEO, Sonali Bloom, just published a new piece in Forbes on why the organizations that win aren't always the leanest ones. They're the ones built to absorb disruption without stopping.

In clinical research, that's not a theoretical concept. Protocol changes, site challenges, vendor drop-outs, accelerated timelines. These aren't edge cases. They're the job.

Sonali breaks down four operating disciplines that separate flexible organizations from fragile ones, including how to protect capacity, build modular operations, and practice change before you're forced to respond.

Worth a read if you lead teams where the plan rarely survives first contact.
🔗 Read the full article: https://hubs.ly/Q04lsR3c0

06/12/2026

Recently, our CEO Sonali Bloom joined health equity leaders at the 2026 Allies Breakfast ahead of the Health Equity Trends Summit in Massachusetts.

The throughline of the conversation: access to care doesn't happen by accident. It takes partnership, listening, and a shared commitment to removing the barriers that keep too many people from preventive and primary care.

That's the work we do every day at 20/20 Onsite. Whether we're bringing eye care to schools or clinical trial participants, the goal is the same: make high-quality care easier to access for the people who face the greatest barriers to getting it.

06/10/2026

Another 20/20 Onsite unit is heading out to support clinical trials across the country.

Our newest LSU7, is built to deliver certified, high-quality ophthalmic assessments wherever a study needs us. Equipped with OCT, Clarus UWF, and a full OD lane, this unit helps us continue expanding point-of-need trial support while protecting ocular endpoints and keeping patients closer to where they live.

As demand grows, so does our ability to deliver trusted ophthalmic trial ex*****on nationwide.

06/08/2026

As we get ready for the World Orphan Drug Congress USA, our team is especially looking forward to the conversations happening across the rare disease community.

The event brings together pharma, biotech, regulators, patient advocates, payers, investors, and solution providers focused on advancing orphan drug development and improving access to therapies for patients with rare diseases.

For Keenan Siciliano, the focus is connecting with people across the rare disease community, hearing different perspectives, and learning more about innovative approaches to improving patient access.

For Sam Larberg, the focus is on hearing how sponsors are applying innovative trial designs in complex development programs, including gene therapies and ultra-rare diseases, and learning how teams are building more patient-centric trials through advocacy group partnerships.

We are looking forward to meaningful conversations about how clinical research can become more accessible, more practical, and closer to the patients who need it most.

Grab a time to meet with Keenan or Sam here: https://hubs.ly/Q04jXrmh0

06/05/2026

When OCT, BCVA, IOP, visual fields, and fundus photography depend on trained personnel, calibrated equipment, and participant access, every logistics gap becomes a data risk.

This article breaks down how point-of-need ex*****on can help protect ocular endpoints, reduce trial friction, and support protocol adherence.

Read the full article: https://hubs.ly/Q04f3DqN0

06/03/2026

20/20 Onsite is heading to the World Orphan Drug Congress USA in Boston, June 9 to 11.

Sam Larberg and Keenan Siciliano will be attending and look forward to connecting with sponsors, CROs, advocacy leaders, and rare disease innovators working to bring new therapies closer to the patients who need them most.

For rare disease trials, patient access, retention, and specialized assessment logistics can become major barriers. That is where point-of-need ophthalmic assessments can help reduce patient burden while supporting protocol-adherent trial ex*****on.

Attending the congress? Reach out to Sam or Keenan to schedule time to connect or grab a time here: https://hubs.ly/Q04jYg4H0

05/28/2026

The FDA has approved the first digital therapeutic for amblyopia in over a decade, opening the door to VR-based binocular training, digital neurotherapy, and innovative vision games that engage both eyes simultaneously.

These breakthrough pediatric trials are exploring treatments that kids actually want to do. Clinical studies show children using VR-based therapy achieved 88% median adherence, compared to traditional patching, which often sees adherence below 50%.

But reaching families for enrollment? That's the real challenge.

20/20 Onsite meets families where they are:
Mobile clinics at schools and community centers
Kid-friendly assessment environments
Flexible scheduling that respects family routines
Refractive measurements, stereo testing, and compliance monitoring, on location

We make participation easy so families can stick with study schedules without long clinic trips.

Because breakthrough pediatric therapies deserve breakthrough enrollment strategies.

05/20/2026

Vision loss from Geographic Atrophy doesn't wait, and neither should innovation.

GA, the advanced dry form of AMD, is finally seeing a breakthrough as treatments emerge. From complement inhibitors to regenerative cell and gene therapy, the pipeline is promising.

But with ~16 GA trials competing for the same patient pool, finding qualified participants is the first challenge. Then comes retention.

That's where we come in.

20/20 Onsite brings two critical solutions:

Pre-screening expertise to identify eligible patients fast in a crowded landscape with overlapping inclusion/exclusion criteria.

Mobile OCT and retinal imaging eliminate travel barriers, ensuring participants stay enrolled, and imaging visits happen on schedule.

82% reduction in travel distance
9% dropout rate (vs 30% industry standard)
Quality ocular endpoint protection

GA trials need more than just participants; they need the right participants who stay through to completion.

Our mobile ophthalmic expertise ensures efficient enrollment and seamless imaging capture without burdening participants or compromising data quality.

Prepared to accelerate your GA study? Let's talk.
https://hubs.ly/Q04cN-Wm0

05/19/2026

For trials with ophthalmic endpoints, the risk is not just whether the trial is managed well. It is whether the endpoint is executed consistently, accurately, and accessibly at the point of need.

In our latest article, we break down what clinical trial management solutions often miss, and why specialized ophthalmic endpoint ex*****on matters for data quality, protocol adherence, and participant retention.

Read the full article: https://hubs.ly/Q04f1-0X0

Address

Boston, MA
02110

Website

http://www.2020onsite.com/

Alerts

Be the first to know and let us send you an email when 20/20 Onsite posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Shortcuts

Want your business to be the top-listed Engineering Company in Boston?